BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

IOMED, Inc. (IOX) Introduces Hybresis(TM) System At APTA CSM


2/15/2007 12:08:37 PM

SALT LAKE CITY, Feb. 15 /PRNewswire-FirstCall/ -- IOMED, Inc. , a leader in the development of active drug delivery systems using iontophoresis, introduced the new Hybresis(TM) System, a first-of-its-kind integrated mini-controller and patch system that uses no lead wires and can deliver in-clinic treatment in as little as three minutes. The product is being showcased to attendees of the American Physical Therapy Association's Combined Section Meeting starting today in Boston.

(Photo: http://www.newscom.com/cgi-bin/prnh/20070215/LATH004)

The Hybresis System consists of a wireless, miniaturized, rechargeable controller that connects directly to an iontophoresis patch and a charging station with four controller bays. The product combines leading-edge design and function with the efficacy, safety and quality that embody IOMED products. Robert J. Lollini, IOMED's President and CEO, said, "The Hybresis System is a quantum leap in iontophoresis technology. For the first time, clinicians have access to a wireless system that offers precise dose control, alternative treatment modes, is easy to set up, and can significantly increase patient throughput due to shortened in-clinic treatment times. Patients who use iontophoresis now have access to a discreet, comfortable system that does not require long wear times."

Mr. Lollini said the Hybresis System could also lend itself to applications in new markets outside of physical and occupational therapy and sports medicine markets, which have long used iontophoresis delivery systems.

IOMED, currently awaiting 510(k) clearance for the Hybresis System from the U.S. Food and Drug Administration, expects to ship the new product within the next several months pending regulatory approval.

IOMED is a leader in developing, manufacturing and marketing active drug delivery systems used primarily to treat acute local inflammation in the physical and occupational therapy and sports medicine markets. The Company is pursuing opportunities to advance its position as a provider of quality, innovative non-invasive medical products that improve patient healthcare. IOMED seeks to accomplish this by expanding its product line, distributing new products, developing strategic partnerships, and through acquisitions. To find out more about IOMED, Inc. , visit our website at www.iomed.com.

Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20070215/LATH004AP Archive: http://photoarchive.ap.orgAP PhotoExpress Network: PRN2PRN Photo Desk, photodesk@prnewswire.comIOMED, Inc.

CONTACT: Brian Mower, CFO, +1-801-975-1191, bmower@iomed.com, or JessicaBarrett, Director, Sales and Marketing, +1-801-975-1911,jbarrett@iomed.com, both of IOMED, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES